Kemwell Acquires US Delivery Development Firm

By Dan Stanton

- Last updated on GMT

Kemwell buys Cirrus
Kemwell buys Cirrus

Related tags Research triangle park Route of administration

Kemwell has positioned a foothold in the US with the acquisition of drug delivery research firm Cirrus Pharmaceuticals.

Cirrus, based in Research Triangle Park, North Carolina, specializes in dosage form development via a number of delivery routes and will become a subsidiary of Kemwell Biopharma, complementing its facilities in Sweden and India.

“With this acquisition, Kemwell now has an established platform in the US market,”​ Kemwell’s VP of Corporate Development Karan Bagaria told

The acquisition will allow Kemwell to offer complete development solutions. Bagaria said: “Customers will get access to early development services in the US and cost-effective late-stage development and GMP manufacturing from our facilities in India and Sweden.”

Cirrus’ experience in inhalation, parenteral, transdermal, topical and liquid dosage forms was also praised by President R&D at Kemwell, Dr. Ninad Deshpanday, who said the deal would allow faster time-to-clinic for products and therefore a lower cost for customers.

Dr. Anthony Hickey, Cirrus’ President, added: “The acquisition will transform Cirrus into a global player in R&D services by significantly strengthening our capabilities in inhalation R&D and increasing offerings in other areas such as oral solids dosage forms.”

Financial details have not been divulged though Mark Phillips of Jacobs Capital who helped broker the deal said – in the Triangle Business Journal​ – all 60-odd jobs at Cirrus should be safe.

Growth and Expansion

Kemwell’s Director of Corporate Development Christian Ahlmark told at this year’s Interphex in New York the firm was expanding its lab footprint on the East Coast to cater for customers’ formulation development, expertise and analyticals, though the firm said neither then nor now if this was in regards to the Cirrus deal.

However, the acquisition does form part of Kemwell’s growth strategy which has seen the firm recently complete its 7,500 sq ft GMP plant expansion​ in Bangalore, India and add an additional 1,500 sq ft of lab space​ to expand its analytical services.

Bagaria said: “We will now continue our efforts to grow the pharmaceutical development business by adding additional capabilities and expertise.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers